United States

Johnson & Johnson (JNJ)

JNJ on New York Consolidated

28 Apr 2017
Change (% chg)

$-0.27 (-0.22%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Latest Key Developments (Source: Significant Developments)

Genmab announces new late stage combination study of Daratumumab in multiple myeloma
9:26am EDT 

April 28 (Reuters) - Genmab A/S ::Genmab announces new phase III combination study of Daratumumab in multiple myeloma.Study is expected to start in Q2 2017 and is designed to confirm results from MMY1001 study.Prescription drug user fee act date of June 17, 2017 for Daratumumab.Janssen Research with European myeloma network plans to start phase III study of Daratumumab in relapsed and refractory multiple myeloma.  Full Article

J&J increase qtrly dividend by 5 pct to $0.84 per share
Thursday, 27 Apr 2017 10:46am EDT 

April 27 (Reuters) - J&J ::Johnson & johnson announces dividend increase of 5.0 percent.Sets quarterly dividend of $0.84 per share.  Full Article

Actelion says J&J deal on track to close towards end of Q2
Thursday, 27 Apr 2017 01:07am EDT 

April 27 (Reuters) - Actelion Ltd :Publication of the definitive notice of the end result of actelion tender offer.Says publication of definitive notice of end result of actelion tender offer.Says transaction remains on track to close towards end of q2 of 2017.  Full Article

FDA approves Renflexis, biosimilar to Remicade
Friday, 21 Apr 2017 03:54pm EDT 

April 21 (Reuters) - FDA::FDA approves Renflexis, biosimilar to Remicade.  Full Article

Johnson & Johnson sees Actelion adding 35-50 cents to 2018 EPS
Tuesday, 18 Apr 2017 09:36am EDT 

April 18 (Reuters) - Johnson & Johnson :Johnson & johnson sees Actelion acquisition adding 35-50 cents to EPS in 2018.J&J CFO says continues to evaluate options for diabetes business, including partnerships, divestitures.  Full Article

Genmab Q1 net sales of Darzalex at $255 million
Tuesday, 18 Apr 2017 06:55am EDT 


Johnson & Johnson Q1 earnings per share $1.61
Tuesday, 18 Apr 2017 06:40am EDT 

April 18 (Reuters) - Johnson & Johnson :Johnson & Johnson reports 2017 first-quarter results:.Q1 earnings per share $1.61.Q1 sales $17.8 billion versus I/B/E/S view $18.02 billion.Q1 earnings per share view $1.76 -- Thomson Reuters I/B/E/S.Sees FY 2017 adjusted earnings per share $7.00 to $7.15.Q1 adjusted non-GAAP earnings per share $1.83 excluding items.Sees FY 2017 sales $75.4 billion to $76.1 billion.J&J says acquisition of Actelion remains on track to close in Q2.J&J says worldwide consumer sales of $3.2 billion for Q1 2017 represented an increase of 1.0% versus prior year.J&J says excluding items, qtrly worldwide sales increased 1.2%, domestic sales decreased 0.7% and international sales increased 3.4%.J&J says worldwide pharmaceutical sales of $8.2 billion for Q1 2017 represented an increase of 0.8% versus prior year.Company is now including estimated impact of Actelion transaction in its financial guidance.J&J says worldwide medical devices sales of $6.3 billion for q1 2017 represented an increase of 3.0% versus prior year.Q1 2017 worldwide Velcade sales $ 280 million versus $274 million in Q4 2016.Q1 2017 worldwide Zytiga sales $523 million versus $519 million in Q4 2016.Q1 worldwide Remicade sales $1,672 million versus $1,624 million in Q4 2016.FY2017 earnings per share view $7.06, revenue view $74.88 billion -- Thomson Reuters I/B/E/S.Q1 2017 worldwide Invokana/Invokamet sales $284 million versus $371 million in Q4 2016.  Full Article

Phagelux announces collaboration with Johnson & Johnson Innovation for new antibacterial solution
Wednesday, 12 Apr 2017 07:00am EDT 

Johnson & Johnson - : Phagelux Inc announces collaboration with Johnson & Johnson innovation for new antibacterial solution . Reached an agreement with Johnson & Johnson Consumer Inc to collaborate on development of one or more skin care products . Deal was facilitated by Johnson & Johnson innovation . Under deal terms between parties, co will be responsible for developing products utilizing its patented or patent pending technologies .Under deal terms Johnson & Johnson consumer shall provide specified financial support, access to certain skin care and formulation know-how.  Full Article

Geron Corp and Janssen Research & Development LLC has completed second internal data reviews of Imerge and Imbark
Monday, 10 Apr 2017 07:30am EDT 

Geron Corp : Geron Corp - Janssen Research & Development, LLC has completed second internal data reviews of Imerge and Imbark . Geron Corp - For imerge, benefit/risk profile of Imetelstat in treated patients supports continued development in lower risk myelodysplastic syndromes . Geron-For Imbark, current results suggest clinical benefit, potential os benefit associated with Imetelstat treatment in relapsed or refractory myelofibrosis . Geron Corp - For Imerge, a data package and proposed trial design refinements are planned to be provided to FDA . Geron Corp - For Imbark, trial will continue unchanged to evaluate maturing efficacy and safety data, including an assessment of overall survival .Geron Corp - If part 2 of imerge is initiated, Geron expects this phase 3 stage of Imerge to be opened for patient enrollment in Q4 of 2017.  Full Article

PeptiDream enters into collaboration with Janssen Pharmaceuticals
Friday, 7 Apr 2017 06:06am EDT 

PeptiDream Inc <4587.T> : Says it entered into a multitarget discovery and optimization collaboration with Janssen Pharmaceuticals, inc, one of the Janssen Pharmaceutical Companies of Johnson & Johnson , on April 7 . Says it will use its proprietary Peptide Discovery Platform System (PDPS) technology to identify macrocyclic/constrained peptides against multiple metabolic and cardiovascular targets of interest selected by Janssen, and to optimize hit peptides into therapeutic peptides or small molecule products . Says Janssen also holds an exercisable option to peptide-drug conjugate (PDC) use and applications . Says Janssen will have the right to develop and commercialize all compounds resulting from the collaboration . Says it will receive undisclosed upfront payment and research funding and is eligible to receive preclinical, clinical, and commercialization milestone payments potentially totaling up to $1.15 billion .In addition, it is eligible to receive royalties on sales of any products that arise from the collaboration.  Full Article

More From Around the Web

Lazard profit beats estimates as deal-making picks up

Lazard Ltd reported a higher-than-expected quarterly profit, mainly driven by growth in its financial advisory business as cross-border mergers and acquisitions got off to the strongest start in a decade.